Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Dow
Deloitte
AstraZeneca
Healthtrust
Colorcon
Chinese Patent Office
Covington

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,856,346

« Back to Dashboard

Which drugs does patent 5,856,346 protect, and when does it expire?

Patent 5,856,346 protects CLEVIPREX and is included in one NDA.

This patent has forty patent family members in thirty countries.
Summary for Patent: 5,856,346
Title: Short-acting dihydropyridines
Abstract:Compounds of the general formula ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, chloro, bromo, nitro, cyano, trifluoromethyl, and R.sub.3 and R.sub.4 are independently selected from straight or branched lower (1-5 carbon atoms) alkyl groups, and including all optical isomers, provided that when R.sub.3 is methyl and R.sub.4 is tert.-butyl, then R.sub.1 /R.sub.2 are not hydrogen/hydrogen, hydrogen/2'-trifluormethyl, 2'-chloro/3'-chloro, and when R.sub.3 is methyl and R.sub.1 /R.sub.2 is hydrogen/3'-nitro, then R.sub.4 are not methyl, ethyl, propyl, iso-propyl, tert.-butyl, processes for their preparation, pharmaceutical preparations containing them and the use of the compounds in lowering the blood pressure.
Inventor(s): Andersson; Kjell Hjalmar (Fjar.ang.s, SE), Nordlander; Margareta (Askim, SE), Westerlund; Rolf Christer (Molndal, SE)
Assignee: Astra Aktiebolag (Sodertalje, SE)
Application Number:08/356,224
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 5,856,346

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-001 Aug 1, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE ➤ Try a Free Trial
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-002 Aug 1, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE ➤ Try a Free Trial
Chiesi Usa Inc CLEVIPREX clevidipine EMULSION;INTRAVENOUS 022156-003 Nov 8, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,856,346

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9303657Nov 05, 1993
PCT Information
PCT FiledNovember 03, 1994PCT Application Number:PCT/SE94/01031
PCT Publication Date:May 11, 1995PCT Publication Number: WO95/12578

International Patents Family Members for US Patent 5,856,346

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 194330 ➤ Try a Free Trial
Australia 685532 ➤ Try a Free Trial
Australia 8119694 ➤ Try a Free Trial
Brazil 9407946 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Cantor Fitzgerald
Chubb
Johnson and Johnson
Express Scripts
Federal Trade Commission
McKinsey
Dow
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.